title: Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo.
abstract: Venous thromboembolism constitutes one of the main causes of death during the progression of a cancer. We previously demonstrated that tissue factor (TF)-bearing cancer cell-derived microparticles accumulate at the site of injury in mice developing a pancreatic cancer. The presence of these microparticles at the site of thrombosis correlates with the size of the platelet-rich thrombus. The objective of this study was to determine the involvement of TF expressed by cancer cell-derived microparticles on thrombosis associated with cancer. We observed that pancreatic cancer cell derived microparticles expressed TF, its inhibitor tissue factor pathway inhibitor (TFPI) as well as the integrins αvβ1 and αvβ3. In mice bearing a tumor under-expressing TF, a significant decrease in circulating TF activity associated with an increase bleeding time and a 100-fold diminished fibrin generation and platelet accumulation at the site of injury were observed. This was mainly due to the interaction of circulating cancer cell-derived microparticles expressing TFPI with activated platelets and fibrinogen. In an ectopic model of cancer, treatment of mice with Clopidogrel, an anti-platelet drug, decreased the size of the tumors and restored hemostasis by preventing the accumulation of cancer cell-derived microparticles at the site of thrombosis. In a syngeneic orthotopic model of pancreatic cancer Clopidogrel also significantly inhibited the development of metastases. Together, these results indicate that an anti-platelet strategy may efficiently treat thrombosis associated with cancer and reduce the progression of pancreatic cancer in mice.
authors.affiliation: Aix Marseille Université, INSERM UMR-S1076, 13385, Marseille, France.
authors.forename: Soraya
authors.initials: S
authors.lastname: Mezouar
authors.forename: Roxane
authors.initials: R
authors.lastname: Darbousset
authors.forename: Françoise
authors.initials: F
authors.lastname: Dignat-George
authors.forename: Laurence
authors.initials: L
authors.lastname: Panicot-Dubois
authors.forename: Christophe
authors.initials: C
authors.lastname: Dubois
mesh_terms: D000818:Animals; D001777:Blood Coagulation; D015153:Blotting, Western; D055252:Cell-Derived Microparticles / Q000378:metabolism*; D000077144:Clopidogrel; D004195:Disease Models, Animal; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D016023:Integrins / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis; D019007:P-Selectin / Q000378:metabolism*; D010190:Pancreatic Neoplasms / Q000150:complications / Q000473:pathology / Q000517:prevention & control*; D015539:Platelet Activation; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013925:Thromboplastin / Q000037:antagonists & inhibitors / Q000378:metabolism; D013927:Thrombosis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
chemical_list: D016023:Integrins; D019007:P-Selectin; D010975:Platelet Aggregation Inhibitors; D012333:RNA, Messenger; D013925:Thromboplastin; D000077144:Clopidogrel; D013988:Ticlopidine
keywords: microparticles; pancreatic cancer; platelets; thrombosis; tissue factor